4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $810,828.70 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 58,333 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $13.90, for a total value of $810,828.70. Following the transaction, the insider directly owned 767,486 shares of the company’s stock, valued at $10,668,055.40. The trade was a 7.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

David Kirn also recently made the following trade(s):

• On Monday, August 3rd, David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.05, for a total value of $124,770.75.
• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.03, for a total transaction of $189,171.75.
• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.87, for a total transaction of $548,364.96.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62.

4D Molecular Therapeutics Stock Up 3.7%

Shares of NASDAQ FDMT opened at $15.22 on Friday. The stock has a market cap of $840.75 million, a PE ratio of -5.79 and a beta of 2.74. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics, Inc. has a 12-month low of $6.47 and a 12-month high of $16.93. The company has a 50-day moving average of $12.79 and a 200 day moving average of $10.85.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The business had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.62 million. As a group, sell-side analysts predict that 4D Molecular Therapeutics, Inc. will post -4.07 EPS for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds have recently modified their holdings of the business. Jupiter Topco LLC purchased a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at about $76,466,000. Janus Henderson Group PLC boosted its stake in 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after buying an additional 611,276 shares during the period. BlackRock Inc. acquired a new stake in shares of 4D Molecular Therapeutics during the second quarter valued at about $60,463,000. Trails Edge Capital Partners LP purchased a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at approximately $29,631,296. Finally, Armistice Capital LLC raised its stake in shares of 4D Molecular Therapeutics by 76.6% in the 4th quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock valued at $14,520,000 after acquiring an additional 840,000 shares during the period. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on FDMT. Cantor Fitzgerald raised shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price target on the stock in a research report on Monday, September 14th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. The Goldman Sachs Group reissued a “buy” rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Finally, HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.56.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.